Tickr
Home Explore Daily Brief Market Watchlists Portfolio
Research
Catalysts Signal Factory Screener Market News Event Calendar Valuation Plot Heat Map Top Investors Industry Trends Options
AI Assistant Notifications Account
United Therapeutics Corporation logo

United Therapeutics Corporation (UTHR) Stock Ticker

NASDAQ: UTHR · Healthcare · Biotechnology
$485.52+0.69%
USD · as of 2026-09-28 · market cap $20.2B
Open UTHR in TickrDownload for iPhone

UTHR right now

Options expect by Oct 6±5.2%
Options expect by Oct 29±10.9%
Priced in for Nov 4 earnings±11.9%
IV rank (30-day)33% · fair
From Tickr's live models · 2026-09-29. Not investment advice.

Market factors today

Tickr 500 vs S&P 500+0.49%+1.0% MTD
Momentum L/S+1.35%+15.1% MTD
High-beta momo L/S+1.46%+22.2% MTD
Rate sensitivity L/S+1.91%+6.9% MTD
Oil sensitivity L/S-2.54%-5.3% MTD
Unprofitable tech-1.43%+3.7% MTD

Unlock the full UTHR picture

🔒 Implied move chart & probabilities
🔒 Live options flow
🔒 AI analysis & chat on UTHR
🔒 Catalysts & earnings
🔒 Strategy Lab
🔒 Financials & estimates
Start your 7-day free trial

About United Therapeutics Corporation

United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.

UTHR stock facts

Ticker symbolUTHR
ExchangeNASDAQ Global Select
SectorHealthcare
IndustryBiotechnology
Market cap$20.2B
CEOMartine A. Rothblatt
Employees1,400
HeadquartersSilver Spring, MD, US
IPO date1999-06-17
Websitewww.unither.com

What you can see for UTHR on Tickr

Live UTHR price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the UTHR report.

Rankings

Largest Healthcare companiesLargest companies by market cap

FAQ

What is the ticker symbol for United Therapeutics Corporation?

The ticker symbol for United Therapeutics Corporation is UTHR, listed on the NASDAQ Global Select.

What is UTHR?

United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for…

HomeExploreMarketLists
All pages